All In Biotech

Drug Trial Radar · NCT04210375

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

Sep 21, 2020

Primary completion

Jun 8, 2023

Study completion Jul 7, 2023

Sponsor

Lead sponsor
Salubris Biotherapeutics IncIndustry
Sponsor type
Industry
First posted
Dec 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in subjects 18 to 80 years of age with HFrEF ≤40%. Initially 5 cohorts are planned with the option to expand the study to a total of 7 cohorts. The size of the cohorts will range from 5 to 9 subjects. Each cohort will include one single active unblinded sentinel subject receiving a single IV dose of JK07 prior to randomized single dose administration of JK07 or placebo \[3:1\] in the remainder of the cohort.

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

  • JK07Drug

    Recombinant fusion protein consisting of a fully humanized immunoglobulin G1 monoclonal antibody and an active polypeptide fragment of the human growth factor NRG-1

  • Matching PlaceboDrug

    Vehicle control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Treatment-emergent Adverse Events [Safety and Tolerability]Time frame: Screening to 30 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arizona College of Medicine

    Tucson, Arizona

  • Stanford University Medical Center

    Stanford, California

  • Harvard Medical School/ Massachusetts General Hospital

    Boston, Massachusetts

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health Science University Hospital

    Portland, Oregon

  • University of Texas Southwestern

    Dallas, Texas

  • Houston Methodist Hospital

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.